Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows [Fortune]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Fortune
Lynparza (olaparib) , a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca , showed clinically meaningful improvements in overall survival, among other promising findings, in people with germline BRCA-mutated (gBCRCAm), HER2-negative high-risk early breast cancer . About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo. Long-term results of the OlympiA phase 3 trial were presented Dec. 11 at the San Antonio Breast Cancer Symposium “The durable long-term efficacy seen in the OlympiA study reinforces Lynparza as an important treatment option for those living with this truly challenging, very aggressive form of breast cancer,” Dr. Eliav Barr , senior vice president, head of global clinical development, and chief medical officer of Merck Research Laboratories , said in a news release about the findings. HER2-negative refers to cancer cells whose surfaces lack a protein called human ep
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Why Astrazeneca (AZN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
- Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- 8MM Respiratory Syncytial Virus Prophylaxis Market Drug Analysis Report: Prophylactic Options to Continue to Diversify Due to Strength of Late-Stage Pipeline - Forecast to 2030 [Yahoo! Finance]Yahoo! Finance
- Ionis Gets FDA Approval for Rare Disease Drug Tryngolza [Yahoo! Finance]Yahoo! Finance
- ATTENTION AZN SHAREHOLDERS: Investors who Lost Money on AstraZeneca PLC are Urged to Contact Levi & Korsinsky about an Ongoing InvestigationAccesswire
AZN
Sec Filings
- 12/16/24 - Form 6-K
- 12/5/24 - Form 6-K
- 12/4/24 - Form 6-K
- AZN's page on the SEC website